TNYA earnings analysis
What we found in TNYA's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Tenaya Therapeutics reported significant improvements in its Q1 2026 financials, with a net loss reduced to $19.3 million from $26.9 million over the same quarter last year. This was marked by a successful collaboration with Alnylam Pharmaceuticals which contributed to collaboration revenues of $0.2 million, indicating an upward trend in operational efficiency despite ongoing losses.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Decreased Net Loss from Prior Year
- Net loss decreased to $19.3 million in Q1 2026, from $26.9 million in Q1 2025, marking a 28% improvement.
- Collaboration Revenue Started
- Collaboration revenue of $0.2 million reported for Q1 2026, compared to none in the prior year.
- Reduction in Operating Expenses
- Total operating expenses dropped by 26%, from $27.5 million in Q1 2025 to $20.3 million in Q1 2026.
- Improvement in R&D Expenses
- Research and development expenses were reduced to $14.8 million in Q1 2026, a decrease of 30% from $21.1 million in Q1 2025.
- Cash Position Remains Strong
- As of March 31, 2026, cash and cash equivalents totaled $80.9 million, providing stability amidst ongoing losses.
- Continued Clinical Advancements
- Ongoing clinical trials for TN-201 and TN-401 expected to bolster future revenue potential.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Regulatory Approval Risks
- With ongoing reliance on collaborations, any delays or failures in meeting regulatory requirements could impact clinical trial timelines.
- Operational Losses Persist
- Despite improvements, continued operational losses remain a risk with accumulated deficit of $624.3 million.
- Dependence on Third-Party Manufacturers
- Reliance on third-party suppliers for raw materials and clinical trial management could lead to supply disruptions.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.09
What they said about what is next.
No specific numeric guidance was provided for revenue or EPS in this 10-Q filing.
The filing reads better than the one before it.
What came before.
- 10-K · March 11, 2026
- Tenaya is a clinical-stage cardiovascular-focused biotech advancing two AAV9 gene therapies (TN-201 for MYBPC3 HCM and TN-401 for PKP2 ARVC) and a selective HDAC6 small molecule (TN-301). The 10-K reports full-year…
- 10-Q · November 10, 2025
- Tenaya reported improved operating results in Q3 2025 with lower operating expenses and a narrower net loss, but remains unprofitable and reliant on financing. Cash and liquidity were materially strengthened during the…
- 10-Q · May 7, 2025
- Tenaya reported a narrower operating loss and improved EPS in Q1 2025 driven by lower R&D and G&A, while completing a March follow-on that materially bolstered liquidity. Cash and equivalents rose to $53.8M (and total…
- 10-Q · November 6, 2024
- Tenaya reported an improving operating profile in Q3 2024 with total operating expenses of $26,711 (in thousands), down from $30,920 in Q3 2023, and a narrower net loss of $25,634 (in thousands) (EPS of $(0.30) vs…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing TNYA makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever